These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 11895923)

  • 21. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.
    Xia S; Zhao Y; Yu S; Zhang M
    Cancer Biother Radiopharm; 2010 Jun; 25(3):317-23. PubMed ID: 20578837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signaling pathways in NSCLC as a predictor of outcome and response to therapy.
    Gupta AK; Soto DE; Feldman MD; Goldsmith JD; Mick R; Hahn SM; Machtay M; Muschel RJ; McKenna WG
    Lung; 2004; 182(3):151-62. PubMed ID: 15526754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skp2, p27kip1 and EGFR assessment in head and neck squamous cell carcinoma: prognostic implications.
    Carracedo DG; Astudillo A; Rodrigo JP; Suarez C; Gonzalez MV
    Oncol Rep; 2008 Sep; 20(3):589-95. PubMed ID: 18695910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
    Ueno S; Sudo T; Oka N; Wakahashi S; Yamaguchi S; Fujiwara K; Mikami Y; Nishimura R
    Int J Gynecol Cancer; 2013 Jul; 23(6):1084-91. PubMed ID: 23792604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy.
    Liang K; Jin W; Knuefermann C; Schmidt M; Mills GB; Ang KK; Milas L; Fan Z
    Mol Cancer Ther; 2003 Apr; 2(4):353-60. PubMed ID: 12700279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
    Gupta AK; Cerniglia GJ; Mick R; Ahmed MS; Bakanauskas VJ; Muschel RJ; McKenna WG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):846-53. PubMed ID: 12788194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
    Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
    Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin.
    Adi S; Wu NY; Rosenthal SM
    Endocrinology; 2001 Jan; 142(1):498-501. PubMed ID: 11145615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.
    Liu FY; Zhao ZJ; Li P; Ding X; Zong ZH; Sun CF
    Br J Oral Maxillofac Surg; 2010 Jun; 48(4):291-6. PubMed ID: 19615795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
    Kim IA; Bae SS; Fernandes A; Wu J; Muschel RJ; McKenna WG; Birnbaum MJ; Bernhard EJ
    Cancer Res; 2005 Sep; 65(17):7902-10. PubMed ID: 16140961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
    Bancroft CC; Chen Z; Yeh J; Sunwoo JB; Yeh NT; Jackson S; Jackson C; Van Waes C
    Int J Cancer; 2002 Jun; 99(4):538-48. PubMed ID: 11992543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.
    Carón RW; Yacoub A; Li M; Zhu X; Mitchell C; Hong Y; Hawkins W; Sasazuki T; Shirasawa S; Kozikowski AP; Dennis PA; Hagan MP; Grant S; Dent P
    Mol Cancer Ther; 2005 Feb; 4(2):257-70. PubMed ID: 15713897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
    Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
    Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma.
    Semba S; Itoh N; Ito M; Youssef EM; Harada M; Moriya T; Kimura W; Yamakawa M
    Clin Cancer Res; 2002 Dec; 8(12):3824-31. PubMed ID: 12473596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
    Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
    J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
    Hakariya T; Shida Y; Sakai H; Kanetake H; Igawa T
    Biochem Biophys Res Commun; 2006 Mar; 342(1):92-100. PubMed ID: 16472761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.